americanpharmaceuticalreviewJanuary 16, 2020
Tag: Rockwell , Appointment , Dr. Ellison
Rockwell Medical announced the appointment of Russell H. Ellison, MD, MSc, to its Board of Directors, effective January 9, 2020.
Dr. Ellison has held leadership positions in both emerging biotechnology and large pharmaceutical companies for more than four decades. His broad experience includes board of director, chief executive and medical executive roles, with expertise in medical strategy, clinical development, global medical affairs, regulatory affairs and public health policy in major markets and developing countries. Dr. Ellison has a deep understanding of the renal space based on experiences with companies developing therapeutic products that address kidney disease and renal anemia, including Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors.
"Russell’s broad industry experience with public biotechnology companies and especially his extensive knowledge of the renal and anemia space makes him an ideal addition to our Board. His leadership will serve us well as we commercialize and develop Triferic® (ferric pyrophosphate citrate) for hemodialysis patients around the world, implement our plans for building a leading medical organization, and further the clinical development of our therapeutic platform as we seek to transform the way anemia is managed in a variety of disease states," said John P. McLaughlin, Chairman of the Board of Directors of Rockwell Medical.
"It is an honor to join Rockwell Medical’s Board and to have the opportunity to contribute to the advancement of such an innovative therapeutic. There is a global opportunity for Triferic® (ferric pyrophosphate citrate), and I am eager to work alongside the current Board members and management team to guide the path forward and ensure that patients have access to this unique iron maintenance therapy," said Russell H. Ellison, MD, MSc.
Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, which focused on, among other indications, kidney fibrosis, and successfully completed the company’s strategic sale in December 2018; President and CEO of Bond Biosciences, a biotech start up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors a global investment banking boutique serving companies in the life sciences industry; Chairman and CEO of Assembly Biosciences (formerly, Ventrus Biosciences); Executive Vice President of Paramount Biosciences, Vice President of Clinical Development at FibroGen, Inc. where he played a key role in the completion of a phase 2 trial with a HIF-PH inhibitor in anemia for Chronic Kidney Disease (CKD) patients; Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo; and Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche, Inc. Additionally, Dr. Ellison has previously served as an Independent Board Director for several private and public companies including, among others, Cougar Biotechnology Inc., ProSanos Corporation, Cormedix Inc., a cardio-renal clinical stage company, and Mt. Cook, a urology-focused company.
Dr. Ellison received an MSc from The London School of Tropical Medicine and Hygiene, and an MD from the University of British Columbia.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: